Biotech Startups

Biotechnology company developing therapeutics that target the extracellular matrix in acute and chronic diseases.

1 investor

SymPhysis Medical develops medical devices to treat malignant pleural effusion, a complication affecting late-stage cancer patients. The company's technology, releaze™, is a drainage device designed to improve patient independence and quality of life.

1 investor

Synapse Biomedical develops and commercializes neurostimulation medical devices, including the NeuRx Diaphragm Pacing System (DPS), which uses electrical stimulation of the diaphragm to treat chronic respiratory insufficiency in patients with spinal cord injuries and ALS. The company serves clinicians and patients dependent on mechanical ventilation.

1 investor

Synaptrix develops NOVABLOC, a non-opioid neuromodulation therapy that uses electrical stimulation to provide targeted, long-lasting postoperative pain relief. The device is being evaluated in a US randomized controlled trial for perioperative pain management, aiming to reduce opioid use after surgeries such as knee replacement.

1 investor

SynCardia manufactures the world's first commercially approved total artificial heart for patients with end-stage heart failure awaiting transplant. The company develops and delivers mechanical circulatory support devices as alternatives to heart transplantation for critically ill patients.

1 investor

Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.

1 investor

Synergic Biosolutions makes a food supplement of calcium ions microencapsulated in prebiotic dietary fiber and enriched with vitamin D. The product is designed for higher absorption and bioavailability, using a smaller amount of pure mineral calcium.

1 investor

Synfini provides AI-driven drug discovery collaboration services that help researchers advance targets and hits into optimized, patentable chemistry. The company offers a platform combining virtual screening, scaffold hopping, synthesis planning, and parallel library synthesis to accelerate early-stage drug discovery.

1 investor

1 investor

Synokem is a pharmaceutical contract manufacturing and supply company offering branded and institutional medical products through its own manufacturing, quality, and distribution capabilities.

1 investor

Synova Life Sciences develops technology for biomedical applications, focusing on innovative solutions in the life sciences sector.

1 investor

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases. The company focuses on bringing a differentiated drug candidate through clinical development and commercialisation to address unmet patient needs in rare and debilitating diseases.

1 investor

Synplexity produces large-scale, cost-effective gene libraries for synthetic biology applications using microreactor technology. The company serves researchers in drug discovery, protein engineering, and functional screening across life sciences and biotechnology.

1 investor

SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.

1 investor

Synth-Med develops a drug delivery platform that uses red blood cells to encapsulate therapeutic payloads in nanoparticles and target hard-to-reach tissues, with a lead program delivering a memory-enhancing molecule to the brain for Alzheimer's and other neurodegenerative diseases. The company operates in the biotech and therapeutics sector.

1 investor

SynthBiome designs synthetic growth media that replicate the physiological conditions bacterial pathogens encounter in human infection sites, including media mimicking cystic fibrosis sputum and chronic wound environments. Its models serve researchers and clinical teams for drug development and antibiotic treatment selection.

1 investor

SynThera develops bioactive glass-based biomaterials and specialty glass products for healthcare, industrial, and consumer applications including bone tissue regeneration, dental repair, skincare, and technical glass for electronics and aerospace. The company serves pharmaceutical, medical device, cosmetics, FMCG, and industrial sectors with a focus on high-purity glass materials.

1 investor

Synthesize develops generative AI models that simulate human tissue responses to drugs and diseases for clinical trial design. The company helps biotech and pharmaceutical development teams de-risk trials, identify biomarkers, and extend early-phase data by generating synthetic patient cohorts.

1 investor

Synthetic Design Lab develops engineered therapeutic platforms and AI-driven antibody design technologies for precision medicine and cancer immunotherapy. The company builds protein engineering and antibody drug conjugate solutions for pharmaceutical development.

1 investor

SynVaccine develops technology for the computer-aided design and construction of viral genomes, applying synthetic and computational biology to create viral-based products such as vaccines and viral-based therapeutics. The company targets applications in human pharma and animal health.

1 investor

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.

1 investor

Green World Solutions is an Estonian company behind the Black Stuff brand, which produces dietary supplements designed to support microbiome health and immunity. The company collaborates with an Institute of Innovative Biomedical Technologies and conducts third-party laboratory testing of its natural-ingredient products.

1 investor

T.Rx Capital is a venture capital firm that invests in and helps build early-stage biotech, healthcare, and medical technology companies, focusing on drug discovery, advanced therapeutic modalities, medical devices, diagnostics, and healthcare software.

1 investor

Taaleri Bioteollisuus is an investment manager that runs private equity funds and joint ventures targeting growth companies in the bio-economy and circular-economy markets, focusing on Northern European firms. Its Bioteollisuus I fund invests in new-technology, industrial-scale bioeconomy production facilities in Finland and Europe.

1 investor